Inhibrx, Inc. (INBX)
NASDAQ: INBX · IEX Real-Time Price · USD
34.33
+0.03 (0.09%)
May 2, 2024, 2:10 PM EDT - Market open
Inhibrx Employees
Inhibrx had 172 employees on December 31, 2023. The number of employees increased by 31 or 21.99% compared to the previous year.
Employees
172
Change (1Y)
31
Growth (1Y)
21.99%
Revenue / Employee
$10,465
Profits / Employee
-$1,403,262
Market Cap
1.63B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 172 | 31 | 21.99% |
Dec 31, 2022 | 141 | 29 | 25.89% |
Dec 31, 2021 | 112 | 21 | 23.08% |
Dec 31, 2020 | 91 | 11 | 13.75% |
Dec 31, 2019 | 80 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Addus HomeCare | 34,846 |
Myriad Genetics | 2,700 |
Zai Lab | 2,175 |
Tilray Brands | 1,600 |
Taro Pharmaceutical Industries | 1,554 |
Supernus Pharmaceuticals | 652 |
Beam Therapeutics | 507 |
Harmony Biosciences Holdings | 246 |
INBX News
- 2 months ago - Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results - PRNewsWire
- 2 months ago - INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX - Business Wire
- 3 months ago - Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with Sanofi - PRNewsWire
- 3 months ago - Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline - Investopedia
- 3 months ago - INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders - Business Wire
- 3 months ago - Sanofi to Buy Rare-Disease Assets From Inhibrx - WSJ
- 3 months ago - France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln - Reuters
- 3 months ago - Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline - GlobeNewsWire